HC Wainwright reiterated their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT - Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $22.00 price objective on the stock.
A number of other equities analysts have also recently weighed in on the stock. Robert W. Baird lowered their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday, November 11th. Chardan Capital reaffirmed a "buy" rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, February 6th. Finally, Citigroup began coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, EyePoint Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $26.63.
Get Our Latest Analysis on EYPT
EyePoint Pharmaceuticals Price Performance
EYPT traded down $0.04 on Thursday, hitting $7.09. 767,829 shares of the stock were exchanged, compared to its average volume of 848,212. The firm has a market capitalization of $483.90 million, a price-to-earnings ratio of -3.55 and a beta of 1.41. EyePoint Pharmaceuticals has a 12 month low of $5.54 and a 12 month high of $24.37. The business has a 50-day moving average of $7.25 and a two-hundred day moving average of $8.44.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The company had revenue of $11.60 million for the quarter, compared to the consensus estimate of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. Equities research analysts expect that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Legal & General Group Plc raised its stake in shares of EyePoint Pharmaceuticals by 4.4% during the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock valued at $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of EyePoint Pharmaceuticals by 39.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after buying an additional 1,940 shares in the last quarter. Invesco Ltd. boosted its stake in shares of EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after purchasing an additional 2,177 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of EyePoint Pharmaceuticals by 22.4% in the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock valued at $113,000 after buying an additional 2,782 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of EyePoint Pharmaceuticals by 3.5% in the 4th quarter. Swiss National Bank now owns 100,000 shares of the company's stock worth $745,000 after purchasing an additional 3,400 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.
EyePoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
